Drug Profile


Alternative Names: bis(maltolato)oxavanadium(IV)

Latest Information Update: 27 Feb 2008

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer Gho Pharma; University of British Columbia
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Burns; Type 2 diabetes mellitus

Most Recent Events

  • 02 Apr 2007 No development reported - Phase-II for Burns in USA (IV)
  • 02 Apr 2007 No development reported - Phase-II for Burns in Europe (IV)
  • 19 May 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top